ADVERTISEMENT
Dabrafenib Plus Trametinib for Patients With BRAF-V600E Mutated Lung Cancer
Lyudmila Bazhenova, MD, Professor of Medicine at the University of California, San Diego, California, reviews the treatment options for managing patients with BRAF-mutated lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer in New York.
Dr Bazhenova focused on the BRAF-V600E mutation, explaining the currently approved treatment of combination dabrafenib and trametinib.
Transcript
I'm Dr. Lyudmila Bazhenova, professor of medicine and thoracic medical oncologist at the University of California, San Diego.
Today I will be discussing the management of lung cancer patients who have mutation in a gene called BRAF. About 2% of lung cancer patients will have mutation in BRAF. Compared to melanoma, only 50% of patients with lung cancer have the BRAF mutation called V600E, and that's where we have data on targeted therapy. The combination of dabrafenib and trametinib is approved in that indication for newly diagnosed patients, which results in a response rate of approximately 64% and median progression-free survival of about 10 months.
The medication has a unique side effect profile. It can cause elevated temperatures and some nausea, but overall toxicity is well-managed. It is important to make sure that you test your patients for BRAF mutation, and if you find a BRAF-V600E mutation, the recommended treatment is dabrafenib and trametinib.
What you do for patients with non-V600E mutations is not yet known. There are ongoing clinical trials with the normal BRAF combinations we can use for those patients.
Source
Bazhenova L. BRAF Mutation: What is the Most Appropriate Approach? Presented at: Great Debates & Updates in Lung Cancer; October 14-15, 2022; Brooklyn, New York.
